All News
EULAR 2024 - Day 1 Report
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
EULAR 2024: New drugs for RA?
Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.
Read Article
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs
D2T RA pts characterised by
⏰ Earlier disease
⏰ Later initiation of DMARD therapy
Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
OP0140-When should we give #pneumococcal #vaccine to pts starting MTX?
Study in RA:PCV13 vaccine given 1 month BEFORE starting MTX leads to higher immunological response at 1m, vs pts vaccinated simultaneously w MTX
⏩Vaccinate patients before starting MTX!
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
When patients say their joints are swollen, what does it mean?
Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows:
- some correlation with MRI/USS findings
- predicts RA development
still worthwhile!
#EULAR2024 POS0609 @RheumNow https://t.co/dw2p5Eo26C
David Liew drdavidliew ( View Tweet)
We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives.
Something to be very proud of. Let’s not forget that!
5y mortality from DANBIO 🇩🇰
(still, we still have work to do in seropos RA in men!)
#EULAR2024 OP0162 @RheumNow https://t.co/RfvABXhPvS
David Liew drdavidliew ( View Tweet)
#EULAR2024 @RheumNow https://t.co/nXpDI52R2U
Mrinalini Dey DrMiniDey ( View Tweet)
OP0181- What are the best drugs to treat D2T RA?
In this cohort of 185 pts, switching biologic or JAKi improved disease activity & was considered to be effective for patients with D2TRA, regardless of mode of action
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
OP0165- incidence & risk factors of D2T RA in an early RA cohort
Factors assoc with D2T RA:
🩸 Seropositivity
🦴 Erosions
📈 Disease activity
📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis
#EULAR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events.
Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early!
#EULAR2024 OP0114 @karolinskainst @RheumNow https://t.co/Q8dIHiIYQk
Links:
David Liew drdavidliew ( View Tweet)
#EULARBest
OP0156- validation & prevalence of D2T RA
Data from @BrighamResearch BRASS
In this cohort, the #EULAR definition of D2TRA correctly identified a subset of RA pts who have not achieved low disease activity despite multiple b/ts DMARD treatments
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs
>1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively?
VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed.
I’ll admit, I’m still not game!
#EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov
Links:
David Liew drdavidliew ( View Tweet)
How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis?
Easy to use score derived from 15y data from @UniversityLeeds - can exclude the low-risk so they don’t need to be followed.
#EULAR2024 OP0127 @RheumNow https://t.co/gB0FpUPOFC
Links:
David Liew drdavidliew ( View Tweet)
OP0131 on occurrence & predictors of #DMARD treatment failure in #RA
8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure
In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs
Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA
📈Female sex, high joint count, erosions, pulmonary #comorbidities, depression & fatigue assoc with D2T RA
💊MTX after start of advanced therapy protective of D2T RA
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexposed, especially the first year but also up to two years since first visit in RA patients. Maximum RR for <90 days is observed at 8 months since first visit (RR:… https://t.co/ecK2ylqrRk https://t.co/IQ5QQjExYQ
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Poster tours at #EULAR2024.
A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j
Dr. Antoni Chan synovialjoints ( View Tweet)
OP0072 @RheumNow #EULAR2024
Effects of #Upadacitinib or #Adalimumab on pain in #RA
SELECT-COMPARE Phase 3 study
UPA & ADA led to improvements in pain vs PBO
PtGA & TJC28 pain improvement similar between UPA & ADA
➡️ UPA may be more effective in control of pain than ADA in RA
Mrinalini Dey DrMiniDey ( View Tweet)
#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts
▶️ #Shingrix works
👍Pts followed to 60 months
#EULAR2024
@eular_org @RheumNow
#OP0020 https://t.co/8ORC3Nd2FK
Janet Pope Janetbirdope ( View Tweet)
